. 1.  General guidelines for diagnosis and treatment of colorectal cancer {#s01}
=========================================================================

Attention should be paid to the role of the multidisciplinary team (MDT) in the diagnosis and treatment of colorectal cancer. It is recommended that designated senior attending physicians from colorectal surgery, hepatobiliary surgery, oncology, radiology, imaging, and other relevant departments participate in the MDT, and that the MDT meeting be held at a fixed time and venue. MDT is particularly recommended for patients with liver-limited metastases, late-stage patients with potentially resectable metastases, and patients with middle and low rectal cancers.

. 2.  Diagnostic principles for colorectal cancer {#s02}
=================================================

. 2.1  Colorectal cancer screening of asymptomatic healthy population {#s02.01}
---------------------------------------------------------------------

High-risk population refers to subjects with history of colorectal adenoma, family history of colorectal cancer, or inflammatory bowel diseases. There are different screening recommendations for average-risk and high-risk populations. Colorectal screening annually is recommended for high-risk population. The average-risk subjects at the age of 50 to 74 years should also accept colorectal cancer screening (1-2). The screening includes a risk accessment by questionnaire and fecal immunochemical occult blood test (FIT). The subjects tested positive in FIT or risk accessment should undergo colonoscopy examination (3-8). If neoplastic lesions were found under colonoscopy, biopsy and histological examination are required. All polyps and flat neoplatic lesions should be removed. If no lesion was found under colonoscopy, repeated colonoscopy is recommended in 5 years. If advanced colorectal adenoma (adenoma with diameter ≥1 cm, with villious differentiation, or with high-grade dysplasia) were diagnosed, the patient should undergo colonoscopy once every 1−3 years. The interval of follow-up colonoscopy could be extended to 3−5 years if there is no recurrent adenoma in the last colonoscopy. Recommendations of colorectal cancer screening for subjects with family history of colorectal cancer please refer to*Section 5* of this guideline. Patients with inflammatory bowel disease should discuss with specialist physician to determine follow-up colonoscopy interval.
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. 2.2  Basic diagnostic principles {#s02.02}
----------------------------------

### . 2.2.1  Colorectal cancer diagnosis (*[Table 1](#Table1){ref-type="table"}*) {#s02.02.01}

###### 

Colorectal cancer diagnosis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aim                                                                                                 Class I recommendation                                                                       Class II recommendation                                                                            Class III recommendation
  --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- --------------------------
  Diagnosis                                                                                           Full colonoscopy + biopsy^a^\                                                                Barium enema^b^\                                                                                   ---
                                                                                                      Rectal cancer: digital rectal examination                                                    Virtual colonoscopy\                                                                               
                                                                                                                                                                                                   Rectal cancer: contrast-enhanced CT/MRI pelvic scan; sigmoidoscopy + biopsy; transrectal biopsy\   
                                                                                                                                                                                                   Colon cancer: contrast-enhanced abdominal/pelvic CT; exploratory surgery                           

  Staging-primary tumors (subjects with a confirmed diagnosis by colonoscopy)                         Rectal cancer: high resolution pelvic MRI scan^c^; Endoscopic rectal ultrasound (ERUS)^d^\   Rectal cancer: contrast-enhanced pelvic CT\                                                        ---
                                                                                                      Colon cancer: contrast-enhanced chest/abdominal/pelvic CT^e^                                 Colon cancer: noncontrast chest CT scan and contrast-enhanced abdominal/pelvic MRI                 

  Staging-distal metastases (subjects with a confirmed diagnosis by colonoscopy)                      Contrast-enhanced chest/abdominal/\                                                          Serum carcinoembroynic antigen/CA199\                                                              Chest X-rays\
                                                                                                      pelvic CT^e^                                                                                 Noncontrast chest CT scan and contrast-enhanced pelvic MRI                                         Pelvic ultrasound

  Staging (ultrasound or CT for patients with suspected liver metastases)                             Contrast-enhanced abdominal MRI                                                              Hepatocyte specific contrast-enhanced MRI                                                          Liver ultrasound

  Staging (suspected metastases according to aforementioned imaging tests but cannot be determined)   PET/CT^f^                                                                                    ---                                                                                                ---

  Examination before major treatment decisions                                                        ---                                                                                          PET/CT^f^\                                                                                         Liver ultrasound
                                                                                                                                                                                                   Hepatocyte specific contrast-enhanced MRI                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### . 2.2.2  Appendix on colorectal cancer imaging staging and diagnosis {#s02.02.02}

Rectal cancer staging (7): T1, Tumor invades submucosa; T2, Tumor invades muscularis propria; T3, Tumor invades subserosa or into non-peritonealised pericolic or perirectal tissues; T4a, Visceral peritoncum invasion (covered by the serosa); and T4b, Surrounding organs and structures invasion. T3 can be further divided into subtypes according to depth of invasion beyond the muscularis propris invasion: T3a (\<1 mm), T3b (1−5 mm), T3c (5−15 mm), and T3d (\>15 mm). Extramural vascular invasion (EMVI) is defined as: tumor extends beyond the rectal wall and tumor thrombosis is seen within extramural vessels (8). Circumferential resection margin (CRM) is defined as primary tumor, metastatic lymph nodes, and EMVI within 1 mm of the mesorectal fascia, surrounding organs and structures (9,10).
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. 2.3  Principles of pathological diagnosis (*[Table 2](#Table2){ref-type="table"}*) {#s02.03}
------------------------------------------------------------------------------------

###### 

Principles of pathological diagnosis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of sample                                                                      Class I recommendation                                                                                                                  Class II recommendation   Class III\                                                        
                                                                                                                                                                                                                                                        recommendation                                                    
  ----------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------- ----------------------------------------------------------------- -----
  Biopsy\                                                                             Size and quantity of tissues                                    Histological identification:\                                                                     Immunohistochemical markers used for differential diagnosis^a^\   ---
  (Includes endoscopic biopsy or core biopsy)                                                                                                         Tumor/non-tumor\                                                                                  MMR protein expression^b^                                         
                                                                                                                                                      Benign/malignant\                                                                                                                                                   
                                                                                                                                                      Histological type\                                                                                                                                                  
                                                                                                                                                      Histological grade                                                                                                                                                  

  Polypectomy\                                                                        Tumor size\                                                     Subtype of adenoma\                                                                               Immunohistochemical markers used for differential diagnosis^a^\   ---
  (Snare resection, endoscopic mucosal resection, endoscopic submucosal dissection)   Pedunculated/sessile                                            Grade of intraepithelial neoplasia (high/low)\                                                    MMR protein expression^b^                                         
                                                                                                                                                      Accompanied with invasive tumor^c^:\                                                                                                                                
                                                                                                                                                      Histological type^d^\                                                                                                                                               
                                                                                                                                                      Histological grade^e^\                                                                                                                                              
                                                                                                                                                      Depth of invasion\                                                                                                                                                  
                                                                                                                                                      Lateral and deep margins\                                                                                                                                           
                                                                                                                                                      Lymphovascular invasion                                                                                                                                             

  Radical surgery sample                                                              Type of specimen\                                               Histological type\                                                                                Immunohistochemical markers used for differential diagnosis^a^\   ---
                                                                                      Tumor site\                                                     Histological grade\                                                                               MSI^k^                                                            
                                                                                      Length of intestinal segment\                                   Depth of invasion\                                                                                                                                                  
                                                                                      Macroscopic subtype\                                            Lymphovascular invasion\                                                                                                                                            
                                                                                      Tumor size\                                                     Perineural invasion\                                                                                                                                                
                                                                                      Distance of tumor from proximal and distal resection margins\   Proximal and distal resection margin\                                                                                                                               
                                                                                      Macroscopic perforation (present/absent)\                       Circumferential resection margin^h^\                                                                                                                                
                                                                                      Macroscopic intactness of mesorectum for TME specimen^f^\       Number of positive lymph nodes/number of total lymph nodes evaluated\                                                                                               
                                                                                      Number, size, and anatomical subsite of lymph nodes^g^          Number of tumor deposits\                                                                                                                                           
                                                                                                                                                      TNM staging^i^\                                                                                                                                                     
                                                                                                                                                      TRG^j^\                                                                                                                                                             
                                                                                                                                                      MMR protein expression^b^                                                                                                                                           

  Table 2 (*continued*)                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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. 2.4  Staging {#s02.04}
--------------

This guideline uses the 2017 UICC/AJCC TNM staging system (8th edition) (1), which is applicable for primary adenocarcinomas, squamous cell carcinomas, and high-grade neuroendocrine tumors in the colon and rectum. This staging system is not suitable for appendix cancer.
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. 3.  Treatment principles for colon cancer {#s03}
===========================================

. 3.1  Treatment of non-metastatic colon cancer {#s03.01}
-----------------------------------------------

### . 3.1.1  Treatment of resectable colon cancer {#s03.01.01}

#### . 3.1.1.1  Endoscopic treatment {#s03.01.01.01}

Colon adenomas or some T1 colon adenocarcinomas can be treated by endoscopic removal (*[Table 3](#Table3){ref-type="table"}*). After resection, postoperative pathology is used to determine the subsequent treatment regimen (*[Table 4](#Table4){ref-type="table"}*).

###### 

Endoscopic treatment strategy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stage                                                                                                     Stratification                                                             Class I\         Class II\        Class III\
                                                                                                                                                                                       recommendation   recommendation   recommendation
  --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------- ---------------- ----------------
  Adenomas and\                                                                                             Pedunculated polyps or non-pedunculated polyps with diameters of 5−20 mm   Trapectomy^a^    EMR              ---
  T1N0 colon adenocarcinoma^a,b,c,d^                                                                                                                                                                                     

  1\. Flat lesions with diameters of 5−20 mm,\                                                              EMR                                                                        ESD              ---              
  2. The wide-base lesion \>10 mm was suspected to be villous adenoma or sessile serrated adenoma/polyp,\                                                                                                                
  3. Suspicious high-grade intraepithelial neoplasia ≤20 mm, which is expected to be completely resected.                                                                                                                

  Mucosa or submucosal adenoma \>20 mm                                                                      PEMR^e^                                                                    ESD              ---              

  1\. Partial T1 (SM \<1 mm) colon cancer,\                                                                 ESD                                                                        Operation        ---              
  2. Transverse spread tumor ≥20 mm,\                                                                                                                                                                                    
  3. Colon polyps with fibrosis, Villous adenoma ≥25 mm.                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Management strategy after polypectomy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathological staging                                 Stratification      Class I\                                                Class II\                                               Class III\
                                                                           recommendation                                          recommendation                                          recommendation
  ---------------------------------------------------- ------------------- ------------------------------------------------------- ------------------------------------------------------- ----------------
  High-grade intraepithelial neoplasia                 NA                  Observation                                             ---                                                     ---

  pT1N0M0\                                             Good prognosis^a^   Observation                                             ---                                                     ---
  Pedunculated polyp with invasive cancer                                                                                                                                                  

  pT1N0M0\                                             ---                 Observation^c^                                          Coloctomy with enbloc removal of regional lymph nodes   ---
  Sessile polyp with invasive cancer                                                                                                                                                       

  pT1N0M0\                                             Poor prognosis^b^   Coloctomy with enbloc removal of regional lymph nodes                                                           Observation
  Pedunculated or sessile polyp with invasive cancer                                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### . 3.1.1.2  Surgical treatment and postoperative adjuvant treatment (*[Table 5](#Table5){ref-type="table"}*, *[6](#Table6){ref-type="table"}*) {#s03.01.01.02}

###### 

Surgical treatment

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical stage                                        Stratification                                       Class I\                                                      Class II\                               Class III\
                                                                                                             recommendation                                                recommendation                          recommendation
  ----------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------- --------------------------------------- ----------------
  cT1−4, N0−2M0\                                        Symptoms that do not require emergency treatment     Coloctomy with enbloc removal of regional lymph nodes^a^      ---                                     ---
  stage I−III                                                                                                                                                                                                      

  cT1−4, N0−2M0\                                        Obstruction                                          Operation^b^                                                  Stent, two-stage radical resection^c^   ---
  stage I−III, symptoms requiring emergency treatment                                                                                                                                                              

  Perforation                                           Operation^d^                                         ---                                                           ---                                     

  Hemorrhage                                            Coloctomy ± enbloc removal of regional lymph nodes   Endoscopic interventional embolization, selective operation   ---                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Postoperative chemotherapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathological stage           Stratification                                                Class I\                                                       Class II\                                      Class III\
                                                                                             recommendation                                                 recommendation                                 recommendation
  ---------------------------- ------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------- ----------------
  Stage I                      T1−2N0M0                                                      Observation (Level 1A evidence)                                ---                                            ---

  Stage II^a,b,c,d,e^          T3N0M0 with low risk factors                                  Observation (Level 1A evidence)                                ---                                            ---

  T3N0M0 with medium\          Fluorouracil monotherapy or observation (Level 1A evidence)   ---                                                            ---                                            
  risk factors                                                                                                                                                                                             

  T3 with high risk factors\   Combined chemotherapy\                                        Fluorouracil monotherapy (only for pMMR) (Level 1B evidence)   Observation\                                   
  or T4N0M0                    (Level 1A evidence)                                                                                                          (Level 3 evidence)                             

  Stage III^d,e^               TanyN+M0                                                      Combined chemotherapy (Level 1A evidence)                      Fluorouracil monotherapy (Level 1B evidence)   ---
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### . 3.1.1.3  Annex: Commonly used adjuvant chemotherapy regimens after colectomy {#s03.01.01.03}

5-FU-based monotherapies

Capecitabine

Capecitabine 1,250 mg/m^2^ each time, twice a day, oral administration, Days 1−14

Repeat every 3 weeks, for 24 weeks

Simplified two-week 5-FU infusion/LV regimen (sLV5FU2)

LV 400 mg/m^2^ Intravenous infusion for 2 h, Day 1

Followed by 5-FU 400 mg/m^2^ by intravenous bolus and then 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion (total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks, for 24 weeks

**Combined chemotherapy regimens**

**CapeOx (also known as XELOX)**

Oxaliplatin 130 mg/m^2^, intravenous infusion for 2 h, Day 1

Capecitabine 1,000 mg/m^2^ each time, twice a day, oral administration, Days 1−14

Repeat every 3 weeks, for 24 weeks

**mFOLFOX6**

Oxaliplatin 85 mg/m^2^ by intravenous infusion for 2 h, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks for 24 weeks
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### . 3.1.2  Treatment of unresectable colon cancer {#s03.01.02}

Radical resection cannot be achieved in some T4b, M0 patients even after combined organ resection. In these patients, 5-FU-based mono-chemotherapy or combination chemotherapy with oxaliplatin or irinotecan, or even triple drug chemotherapy can be used according to the patient's condition (1). Clinical trials on advanced colorectal cancer have also shown that chemotherapy can be combined with bevacizumab or cetuximab (2-5). For some T4b patients with local invasion of the sigmoid colon, local radiotherapy can also be performed to increase the response rate of treatment and increase the probability of conversion (6). Endoscopic stent implantation (7,8) or bypass surgery can be carried out to remove obstruction in T4b colon cancer patients with intestinal obstruction.
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. 3.2  Treatment principles for metastatic colon cancer {#s03.02}
-------------------------------------------------------

### . 3.2.1  Synchronous metastatic colon cancer {#s03.02.01}

#### . 3.2.1.1  Treatment of initially resectable metastatic colon cancer {#s03.02.01.01}

For patients with asymptomatic, resectable synchronous liver-limited metastases, in which there is the possibility of a potential cure, multimodal therapy including surgery and perioperative chemotherapy is recommended. According to the clinical risk score (CRS), the sequence of neoadjuvant chemotherapy and surgery was determined. If the CRS score shows low risk of recurrence (0−2 points), simultaneous or staged resection of colon cancer and metastatic lesions + postoperative adjuvant chemotherapy is recommended. Neoadjuvant chemotherapy before surgery or resection of the primary lesion + neoadjuvant chemotherapy before local treatment of metastatic lesions can also be considered. If the CRS score shows a high risk of recurrence (3−5 points), neoadjuvant chemotherapy is first recommended, followed by colectomy + simultaneous or staged local treatment of metastatic lesions. Colectomy + neoadjuvant chemotherapy + resection/radiofrequency ablation, other local treatment of metastatic lesions + postoperative adjuvant chemotherapy, simultaneous or staged colectomy and resection/radiofrequency ablation, or other local treatment of metastatic lesions + postoperative adjuvant chemotherapy can also be considered.

For colon cancer patients with symptomatic primary lesions (e.g., obstruction, bleeding, perforation) and synchronous liver metastases only, resection of the primary lesion can be treated first to alleviate symptoms. Stent implantation can also be considered for patients with obstruction. Stratified treatment can then be used based on the CRSs, using the same principles as above.

To reduce drug-induced liver injury, the course of neoadjuvant chemotherapy is usually limited to 2−3 months.

Local management methods for metastatic lesions not only include surgery but also radiofrequency ablation, microwave ablation, and stereotactic radiation therapy.

The CRS contains five parameters: lymph node positivity for primary tumor, synchronous metastases or metachronous metastases that are \<12 months from the date of resection of the primary lesion, \>1 liver metastases, preoperative carcinoembryonic antigen (CEA) levels \>200 ng/mL, and maximum diameter of metastasis \>5 cm. Each item scores 1 point. A score of 0−2 points is low while a score of 3−5 points is high. The higher the CRS score, the greater the risk of postoperative recurrence, and the more beneficial the perioperative chemotherapy ( 1,2).

#### . 3.2.1.2  Treatment of initially unresectable metastatic colon cancer {#s03.02.01.02}

Treatment for initially unresectable metastatic colon cancer can be divided into conversion therapy and palliative treatment based on the resectability of the metastatic lesions. As primary lesions present with symptoms of obstruction, bleeding, and perforation, the primary lesion should be treated first. Comprehensive management and treatment should be used under the guidance of the MDT for these patients.

Patients with potentially resectable tumors should undergo conversion chemotherapy first to shrink metastatic lesions, after that the resectability of these lesions should be re-assessed. *[Table 7](#Table7){ref-type="table"}* shows the conversion chemotherapy regimens.

###### 

Conversion chemotherapy for potentially resectable lesions^a,b,c^

  Stratification                                                   Class I recommendation                                    Class II recommendation                                                                                Class III recommendation
  ---------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------
  Suitable for intensive treatment (both RAS and BRAF wild-type)   FOLFOX/FOLFIRI ± cetuximab^d^ (Level 2A evidence)         FOLFOX/CapeOx/FOLFIRI ± bevacizumab (Level 2A evidence); FOLFOXIRI ± bevacizumab (Level 2A evidence)   Hepatic arterial infusion chemotherapy or other local treatments (Level 2B evidence)
  Suitable for intensive treatment (both RAS or BRAF mutations)    FOLFOX/CapeOx/FOLFIRI ± bevacizumab (Level 2A evidence)   FOLFOXIRI ± bevacizumab (Level 2A evidence)                                                            Hepatic arterial infusion chemotherapy or other local treatments (Level 2B evidence)

Palliative therapy mainly consists of systemic therapy.

First-line regimens for palliative therapy

*[Table 8](#Table8){ref-type="table"}* shows first-line regimens for palliative therapy.

###### 

First-line regimens for palliative therapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratification                                                       Class I recommendation                                                                                         Class II recommendation                                                                    Class III recommendation
  -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
  Suitable for intensive treatment (both RAS and BRAF wild-type)       FOLFOX/FOLFIRI ± cetuximab^a,b^ (Level 1A evidence); FOLFOX/CapeOx/FOLFIRI ± bevacizumab (Level 1A evidence)   FOLFOXIRI ± bevacizumab (Level 2A evidence)                                                Hepatic arterial infusion chemotherapy or other local treatments (Level 3 evidence)

  Not suitable for intensive treatment (both RAS and BRAF wild-type)   Fluorouracil monotherapy ± bevacizumab (Level 1A evidence)                                                     Cetuximab monotherapy^a,b^ (Level 2A evidence);\                                           Hepatic arterial infusion chemotherapy or other local treatments (Level 3 evidence)
                                                                                                                                                                                      Dose-reduced dual chemotherapy (FOLFOX/FOLFIRI) ± cetuximab (Level 2A evidence);\          
                                                                                                                                                                                      Dose-reduced dual chemotherapy (FOLFOX/CapeOx/FOLFIRI) ± bevacizumab (Level 2A evidence)   

  Suitable for intensive treatment (both RAS or BRAF mutations)        FOLFOX/CapeOx/FOLFIRI ± bevacizumab (Level 1A evidence)                                                        FOLFOXIRI ± bevacizumab (Level 2A evidence)                                                Hepatic arterial infusion chemotherapy or other local treatments (Level 3 evidence)

  Not suitable for intensive treatment (both RAS or BRAF mutations)    Fluorouracil monotherapy ± bevacizumab (Level 1A evidence)                                                     Dose-reduced dual chemotherapy (FOLFOX/CapeOx/FOLFIRI) ± bevacizumab (Level 2A evidence)   Hepatic arterial infusion chemotherapy or other local treatments (Level 3 evidence)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Second-line regimens for palliative therapy**

In principle, the regimen of second-line treatment should be changed. The original chemotherapy regimen can be used for stop-and-go patients. Targeted therapy drugs can be used in second-line treatment if they are not used in first-line treatment. If first-line chemotherapy is combined with bevacizumab, the chemotherapy regimen can be changed in second-line treatment while retaining bevacizumab (7). If first-line chemotherapy is combined with cetuximab for palliative treatment, cetuximab is not recommended to be used continuously in second-line therapy. The modified XELIRI (irinotecan + capecitabine regimen, mXELIRI) can be used for second-line chemotherapy (8).

**Third-line regimens for palliative therapy**

For patients with both wild-type *RAS* and *BRAF* genes, cetuximab ± irinotecan (for patients who are cetuximab-naive) regorafenib, or clinical trials are recommended. For patients with *RAS* or *BRAF* mutations, regorafenib or clinical trials are recommended.
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### . 3.2.2  Treatment of postoperative recurrence in metastatic colon cancer {#s03.02.02}

For postoperative patients with resectable recurrence disease, please see "*asymptomatic primary lesions*" in *Section 3.2.1.1* on *Treatment of initially resectable metastatic colon cancer*, as these patients do not have primary lesions. For postoperative patients with unresectable recurrence disease, please see "*asymptomatic primary lesions*" in *Section 3.2.1.2* on *Treatment of initially unresectable metastatic colon cancer*.

### . 3.2.3  Annex: Commonly used systemic therapy regimens for metastatic colorectal cancer {#s03.02.03}

**mFOLFOX6**

Oxaliplatin 85 mg/m^2^ by intravenous infusion for 2 h, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks

**mFOLFOX6 + bevacizumab**

Oxaliplatin 85 mg/m^2^ by intravenous infusion for 2 h, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Bevacizumab 5 mg/kg IV, Day 1

Repeat every 2 weeks

**mFOLFOX6 + cetuximab**

Oxaliplatin 85 mg/m^2^ by intravenous infusion for 2 h, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Cetuximab 400 mg/m^2^, IV for more than 2 h for first administration followed by 250 mg/m^2^ IV for more than 60 min. Repeat every week

Or cetuximab IV 500 mg/m^2^, Day 1, infusion for more than 2 h, repeat every 2 weeks

**CapeOx**

Oxaliplatin 130 mg/m^2^ IV for more than 2 h, Day 1

Capecitabine 1,000 mg/m^2^ each time, twice a day, oral administration, Days 1−14 followed by 7 d of rest

Repeat every 3 weeks

**CapeOx + bevacizumab**

Oxaliplatin 130 mg/m^2^ IV for more than 2 h, Day 1

Capecitabine 1,000 mg/m^2^ each time, twice a day, oral administration, Days 1−14 followed by 7 days of rest

Bevacizumab 7.5 mg/kg IV, Day 1

Repeat every 3 weeks

**FOLFIRI**

Irinotecan 180 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h together with irinotecan infusion, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks

**FOLFIRI + bevacizumab**

Irinotecan 180 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h together with irinotecan infusion, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Bevacizumab 5 mg/kg, intravenous infusion, Day 1

Repeat every 2 weeks

**FOLFIRI + cetuximab**

Irinotecan 180 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

LV 400 mg/m^2^ by intravenous infusion for 2 h together with irinotecan infusion, Day 1

5-FU 400 mg/m^2^ by intravenous bolus on Day 1 followed by 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks

Cetuximab 400 mg/m^2^, IV for more than 2 h for first administration followed by 250 mg/m^2^ IV for more than 60 min. Repeat every week

Or cetuximab IV 500 mg/m^2^, Day 1, infusion for more than 2 h, repeat every 2 weeks

**CapIRI**

Irinotecan 180 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

Capecitabine: 1,000 mg/m^2^ each time, twice a day, oral administration, Days 1−7

Repeat every 2 weeks

**CapIRI + bevacizumab**

Irinotecan 180 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

Capecitabine: 1,000 mg/m^2^ each time, twice a day, oral administration, Days 1−7

Bevacizumab 5 mg/kg, intravenous infusion, Day 1

Repeat every 2 weeks

**mXELIRI**

Irinotecan 200 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

Capecitabine: 800 mg/m^2^ each time, twice a day, oral administration, Days 1−14

Repeat every 3 weeks

**mXELIRI + bevacizumab**

Irinotecan 200 mg/m^2^ by intravenous infusion for more than 30−90 min, Day 1

Capecitabine: 800 mg/m^2^ each time, twice a day, oral administration, Days 1−14

Bevacizumab 7.5 mg/kg, intravenous infusion, Day 1

Repeat every 3 weeks

**Capecitabine**

Capecitabine: 1,250 mg/m^2^ each time, oral administration, twice a day, Days 1−14, repeat every 3 weeks

**Capecitabine + bevacizumab**

Capecitabine: 1,250 mg/m^2^ each time, oral administration, twice a day, Days 1−14, repeat every 3 weeks

Bevacizumab 7.5 mg/kg, IV, Day 1, repeat every 3 weeks

**Simplified two-week 5-FU infusion/LV regimen (sLV5FU2)**

LV 400 mg/m^2^ intravenous infusion for 2 h, Day 1

Followed by 5-FU 400 mg/m^2^ intravenous bolus, and then 1,200 mg/(m^2^·d)×2 d by continuous intravenous infusion

(total amount: 2,400 mg/m^2^, infusion for 46−48 h)

Repeat every 2 weeks

**FOLFOXIRI + bevacizumab**

Irinotecan 165 mg/m^2^, intravenous infusion, Day 1

Oxaliplatin 85 mg/m^2^, intravenous infusion, Day 1

LV 400 mg/m^2^, intravenous infusion, Day 1

Followed by 5-FU 1,600 mg/(m^2^·d)×2d, continuous intravenous infusion (total amount 3,200 mg/m^2^, 48 h of infusion)

Bevacizumab 5 mg/kg IV, Day 1

Repeat every 2 weeks

**Irinotecan**

Irinotecan 125 mg/m^2^ by intravenous infusion for more 30−90 min, Day 1, repeat every 3 weeks

Irinotecan 300−350 mg/m^2^ by intravenous infusion for more 30−90 min, Day 1, repeat every 3 weeks

**Cetuximab + irinotecan**

First dose of cetuximab 400 mg/m^2^ by intravenous infusion, followed by 250 mg/m^2^, once every week

Or cetuximab 500 mg/m^2^, once every 2 weeks

Irinotecan 300−350 mg/m^2^ by intravenous infusion, repeat every 3 weeks

Or irinotecan 180 mg/m^2^ by intravenous infusion, repeat every 2 weeks

Or irinotecan 125 mg/m^2^ by intravenous infusion on Day 1 and 8, repeat every 3 weeks

**Cetuximab**

First dose of cetuximab 400 mg/m^2^ by intravenous infusion, followed by 250 mg/m^2^, once every week

Or cetuximab 500 mg/m^2^, once every 2 weeks

**Regorafenib**

Regorafenib 160 mg, oral administration, once a day, Days 1−21, repeat every 28 d

Raltitrexed 3 mg/m^2^ by intravenous infusion in 15 min (+ 50−250 mL 0.9% sodium chloride or 5% glucose).

Repeat every 3 weeks

. 3.3  Colon cancer follow-up {#s03.03}
-----------------------------

Postoperative follow-up for stage I patients: once every 6 months for 5 years. Postoperative follow-up for stage II/III patients: once every 3 months for 3 years, followed by once every 6 months to 5 years, and then once a year. The follow-up should include: 1) Physical examination with an emphasis on digital rectal examination; 2) Blood CEA levels; 3) Liver ultrasonography for stage I/II patients; 4) Chest, abdominal, and pelvic CT once a year for stage III patients or when there are CEA or ultrasound abnormalities; and 5) Colonoscopy examination within 1 year after surgery. If full colonoscopy was not carried out before surgery due to tumor obstruction, examinations should be carried out in 3−6 months after surgery. If no abnormalities are found, follow-up examinations should be carried within 3 years, followed by once every 5 years (1). Follow-up frequency for R0 resection/ablation for stage IV patients with metastases: once every 3 months for 3 years, followed by once every 6 months until Year 5, and then once a year. Follow-up should include: physical examination; blood CEA levels; and enhanced chest, abdominal, and pelvic CT once every 6−12 months. If the patient's physical status does not allow him/her to receive anti-neoplastic treatment due to recurrence, it is not advisable to conduct routine tumor follow-up/monitoring for the patient. PET/CT is only recommended for clinically suspected recurrence while routine imaging is negative, such as persistently elevated CEA. PET examination is not recommended as a routine follow-up/monitoring method.
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. 4.  Treatment principles for rectal cancer {#s04}
============================================

. 4.1  Treatment principles for non-metastatic rectal cancer {#s04.01}
------------------------------------------------------------

### . 4.1.1  Treatment principles for rectal adenoma {#s04.01.01}

Refer to *Section 3.1.1.1 Endoscopic treatment* for treatment of rectal adenomas. Usually different treatment recommendations are given based on the distance between the lesion and the anal verge in high-grade rectal neoplasia. For patients with a distance of ≤8 cm between the lesion and anal verge, it is primarily recommended that transanal local excision or endoscopic resection be performed, followed by transanal endoscopic microsurgery (TEM), laparoscopic or open rectal resection. For patients with a distance of 8−15 cm, endoscopic resection is the treatment of first choice, followed by TEM, laparoscopic, or open rectal resection.

### . 4.1.2  Treatment principles for cT1−2N0 rectal cancer {#s04.01.02}

The treatment principles for cT1−2N0 rectal cancer is radical surgery. Transanal local excision can be considered in cT1N0 patients when it is difficult to perform sphincter-preserving surgery. Radical surgery should be considered if the following pathological situation occur after local excision: poorly differentiated tumors, vascular invasion, positive resection margin, sm3, or T2. Radiotherapy/ chemotherapy is recommended for patients who do not undergo radical surgery (1,2). Concurrent chemoradation can be considered if it is difficult to carry out organ preservation. operation in cT2N0 patients but the patient has a strong intention for organ preservation. The next treatment can be selected according to the extent of tumor response: 1) Watch & wait for patients who have complete clinical response (cCR); 2) Transanal local excision for patients with ycT1 tumors; and 3) Radical rectal cancer surgery for patients with ycT2 tumors. The current international consensus for complete clinical remission (cCR) ( 3) includes: 1) Digital rectal examination: normal; 2) White and flat mucosal scars under the endoscope, accompanied by peripheral capillary telangiectasia, without signs of malignant ulcers or nodulesd; and 3) High resolution MRI in T2 shows completely dark, without moderate intensity signals and lymph nodes; in DW phase, no tumor signal for B800-B1000 and/or, in ADC shows little or no signal, and intestinal wall linear signals in the tumor area. The watch and wait strategy is currently under exploration. There is a need to fully communicate with the patients, with an emphasis for more frequent follow-up and let them know the results of salvage therapy after tumor recurrence. It is recommended that follow-up visits should be carried out every 1−2 months within 2 years. The assessment methods mainly consist of digital rectal examination, endoluminal ultrasound, and functional MR. There is still controversy over the use of biopsy in the scar region of the primary lesion.
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### . 4.1.3  Treatment of cT3/cT4N+ rectal cancer (*[Table 9](#Table9){ref-type="table"}*) {#s04.01.03}

###### 

Treatment of cT3/cT4N+ rectal cancer

  Stage                                                                                                                                           Stratification                                                                                                              Class I recommendation                                                                                         Class II recommendation                                                                                                   Class III recommendation
  ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  cT3N0                                                                                                                                           Middle rectal cancers with peritoneum covered                                                                               Concurrent radiochemotherapy^a^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1A evidence)   Short-course radiotherapy^d^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1B evidence)                 Transabdominal resection^b^ +/− adjuvant therapy^c,e,f^
  Middle rectal cancers without peritoneum covered or lower rectal cancers                                                                        Concurrent radiochemotherapy^a^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1A evidence)                Short-course radiotherapy^d^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1B evidence)      ---                                                                                                                       
  cT4/any N, cT/N1−2, or locally unresectable                                                                                                     None                                                                                                                        Concurrent radiochemotherapy^a^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1A evidence)   Chemotherapy^g^ + concurrent radiochemotherapy^a^ + transabdominal resection^b^ +/− chemotherapy^h^ (Level 2A evidence)   ---
  cT3,4 or N+                                                                                                                                     Medical factors that contraindicate surgical resection are present                                                          Concurrent radiochemotherapy^a^ + transabdominal resection^b^ + adjuvant chemotherapy^c^ (Level 1A evidence)   Chemotherapy^g^ + concurrent radiochemotherapy^a^ + transabdominal resection^b^ +/− chemotherapy^h^ (Level 2A evidence)   ---
  cT3,4N0, any T/N+, or patients who did not undergo preoperative radiotherapy due to contraindications for multimodal therapy or other reasons   pT1−2N0 after transabdominal resection                                                                                      Observation                                                                                                                                                                                                                              ---
  pT3−4N0 or any pT/N1−2 after transabdominal resection                                                                                           Re-evaluation^i^: Adjuvant chemotherapy^c^ + adjuvant radiochemotherapy^a^ + adjuvant chemotherapy^c^ (Level 1A evidence)   Re-evaluation^i^: Adjuvant radiochemotherapy^a^ + adjuvant chemotherapy^c^ (Level 1B evidence)                 ---                                                                                                                       

This section is applicable for midder and lower rectal cancers that were assessed by digital rectal examination and MRI, with a distance from anal verge to the lower edge of tumor \<10 cm. Stratified treatment according to risk level should be carried out under the guidance of high-quality MRI imaging and experienced radiologists.
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. 4.2  Treatment principles for metastatic rectal cancer {#s04.02}
--------------------------------------------------------

### . 4.2.1  Treatment principles for synchronous metastatic rectal cancer (*[Table 10](#Table10){ref-type="table"}*) {#s04.02.01}

###### 

Treatment principles for synchronous metastatic rectal cancer^a^

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratification^b^                                        Class I recommendation                                                              Class II recommendation                                                                   Class III recommendation                                             
  -------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------- -----
  Resectable, ≤ moderate risk of recurrence                Resectable                                                                          Similar to *Section 3.2.1.1 Treatment for initially resectable metastatic colon cancer*                                                                        

  Unresectable                                             Similar to *3.2.1.2 Treatment for initially unresectable metastatic colon cancer*                                                                                                                                                                  

  Resectable, high and extremely high risk of recurrence   Resectable                                                                          Concurrent radiochemotherapy^c^ + systemic therapy^d^ + surgery^e^                        Systemic therapy^d^ ± concurrent radiochemotherapy^c^ + surgery^e^   ---

  Unresectable                                             Systemic therapy^d^\                                                                Short-course radiotherapy + systemic therapy^d^                                           ---                                                                  
                                                           MDT assessment of resectability                                                                                                                                                                                                                    

  Unresectable                                             Resectable                                                                          Systemic therapy^d^ + concurrent radiochemotherapy^c^\                                    Systemic therapy^d^ ± radiotherapy^c^                                ---
                                                                                                                                               MDT assessment of resectability                                                                                                                                

  Unresectable                                             Systemic therapy^d^ ± radiotherapy^c^                                               ---                                                                                       ---                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### . 4.2.2  Treatment principles for postoperative recurrence in metastatic rectal cancer {#s04.02.02}

#### . 4.2.2.1  Diagnosis and treatment principles for local recurrence after rectal cancer surgery {#s04.02.02.01}

When local recurrence after rectal cancer surgery is diagnosed, resectability and history of pelvic radiation should be taken into consideration. For patients with resectable lesions, surgery after radiochemotherapy can be considered in patient without previous radiation, or direct surgery in patient with previous radiation. For unresectable lesions, palliative or conversional chemotherapy and re-evaluation for resectability are recommended.

#### . 4.2.2.2  Treatment principles for rectal cancer with postoperative metastasis {#s04.02.02.02}

Refer to *Section 3.2.2 Treatment of postoperative recurrence in metastatic colon cancer*.

### . 4.3  Rectal cancer follow-up {#s04.03}

Refer to *Section 3.3 Colon cancer follow-up*.

. 5.  Principles of screening for hereditary colorectal cancer and genetic testing {#s05}
==================================================================================

Management strategy after genetic screening is shown in *[Table 11](#Table11){ref-type="table"}*. All colorectal cancer patients should be asked on their family history of cancer and their intestinal polyp status should be determined. Specific disease screening should be carried out for patients who fulfilled the following criteria in regional medical center: 1) Familial adenomatous polyposis (FAP) screening (including colonoscopy examination and FAP genetic screening) is required for individuals with ≥20 polyps in the entire colon and rectum or with a confirmed FAP family member (1); 2) Peutz-Jeghers syndrome (PJ) screening is required for individuals with significant melanosis in the oral mucosa, lips, nose, cheeks, periorbital area, reproductive organs, hands and feet, perianal skin, etc. Patients with confirmed PJ family members also should receive screening. *STK11* gene mutation test is recommended (2); and 3) Patients excluding FAP and PJ syndrome should receive screening for Lynch syndrome. Individuals who fulfilled the following criteria should be suspected of Lynch syndrome family and detected the relevant genes (mismatch repair genes *MLH1*, *MSH2*, *MSH6*, and *PMS2*) (3,4). There are at least two histopathologically diagnosed colorectal cancer patients in the family, and 2 cases of them are first-degree relatives (parents and offspring, or siblings), and meet any one of the following criteria: 1) At least one case with multiple colorectal cancer (including adenomas); 2) At least one with onset of colorectal cancer \<50 years; and 3) At least one with Lynch syndrome associated-extracolonic cancers (including gastric cancer, endometrial cancer, small intestine cancer, ureter and renal pelvis cancer, ovarian cancer, and hepatobiliary cancers) ( 5). After genetic testing, protocols in the following table are used for management and follow-up for those with confirmed pathological germline mutations and mutation carriers. General population screening can be carried out for individuals who are not mutation carriers. For those in which germline mutations cannot be determined, follow-up strategy should be discussed and decided by the doctor and individiuals according to family history and clinical presentations.

###### 

Management strategy after genetic screening

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical assessment                               Recommendation
  ------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Management strategy after genetic screening (6)   1\. Carriers of familial adenomatous polyposis gene mutations:\
                                                    1) Undergo colonoscopy examinations once every year from 10−15 years old.\
                                                    2) If high-grade intraepithelial neoplasia is present in the polyps, prophylactic colectomy is recommended depending on the number and distribution of polyps.\
                                                    2. Carriers of Lynch syndrome gene mutations:\
                                                    1) Carriers of MLH1 or MSH2 mutations: Undergo colonoscopy once every 1−2 years from 20−25 years old; Carriers of MSH6 or PMS2 mutations: Undergo colonoscopy once every 1−2 years from 25−30 years old.\
                                                    2) Undergo gastroduodenoscopy once every 1−2 years from 30−35 years old.\
                                                    3) Prophylactic hysterectomy and bilateral salpingo-oophorectomy can be considered for females who have given birth. For individuals who does not undergo prophylactic surgery, endometrial biopsy once every 1−2 years and regular transvaginal ultrasound as well as serum CA125 test are recommended to monitor endometrial cancer and ovarian cancer.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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